Details

Autor(en) / Beteiligte

• Case, James Brett
• Rothlauf, Paul W.
• Chen, Rita E.
• Liu, Zhuoming
• Zhao, Haiyan
• Kim, Arthur S.
• Bloyet, Louis-Marie
• Zeng, Qiru
• Tahan, Stephen
• Droit, Lindsay
• Ilagan, Ma. Xenia G.
• Tartell, Michael A.
• Amarasinghe, Gaya
• Henderson, Jeffrey P.
• Miersch, Shane
• Ustav, Mart
• Sidhu, Sachdev
• Virgin, Herbert W.
• Wang, David
• Ding, Siyuan
• Corti, Davide
• Theel, Elitza S.
• Fremont, Daved H.
• Diamond, Michael S.
• Whelan, Sean P.J.

Titel

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

Ist Teil von

• Cell host & microbe, 2020-09, Vol.28 (3), p.475-485.e5

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2020

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Antibody-based interventions against SARS-CoV-2 could limit morbidity, mortality, and possibly transmission. An anticipated correlate of such countermeasures is the level of neutralizing antibodies against the SARS-CoV-2 spike protein, which engages with host ACE2 receptor for entry. Using an infectious molecular clone of vesicular stomatitis virus (VSV) expressing eGFP as a marker of infection, we replaced the glycoprotein gene (G) with the spike protein of SARS-CoV-2 (VSV-eGFP-SARS-CoV-2) and developed a high-throughput-imaging-based neutralization assay at biosafety level 2. We also developed a focus-reduction neutralization test with a clinical isolate of SARS-CoV-2 at biosafety level 3. Comparing the neutralizing activities of various antibodies and ACE2-Fc soluble decoy protein in both assays revealed a high degree of concordance. These assays will help define correlates of protection for antibody-based countermeasures and vaccines against SARS-CoV-2. Additionally, replication-competent VSV-eGFP-SARS-CoV-2 provides a tool for testing inhibitors of SARS-CoV-2 mediated entry under reduced biosafety containment. [Display omitted] •Vesicular stomatitis virus encoding the SARS-CoV-2 spike replicates to high titers•Virus propagation is enhanced by a truncation in the cytoplasmic tail of the spike•Neutralization can be assessed by BSL2 and BSL3 high-throughput assays•SARS-CoV-2- and VSV-SARS-CoV-2-based neutralization assays correlate Case, Rothlauf et al. generate a replication-competent vesicular stomatitis virus (VSV) expressing the SARS-CoV-2 spike and compare the neutralizing activity of antibodies with VSV-SARS-CoV-2 to fully infectious SARS-CoV-2. They show that VSV-SARS-CoV-2 is a useful BSL2 surrogate virus, as neutralization profiles strongly correlate with focus-reduction neutralization tests using SARS-CoV-2.